AMRN Projected Dividend Yield

ADR (Sponsored) New/Amarin Corp Plc ( NASDAQ : AMRN )

Amarin a pharmaceutical company that focused on the commercialization and development of therapeutics to improve cardiovascular health. Co.'s primary product, Vascepa® (icosapent ethyl) capsules, is use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. The U.S. Food and Drug Administration (FDA) approved an indication and label for Vascepa based on the results of Co.'s cardiovascular outcomes trial of Vascepa, REDUCE-IT® (Reduction of Cardiovascular Events with EPA ? Intervention Trial). Vascepa is approved by the FDA as an adjunct to tolerated statin therapy for reducing persistent cardiovascular risk in select high risk patients.

20 YEAR PERFORMANCE RESULTS